Autopsy and Case Reports
https://www.autopsyandcasereports.org/article/doi/10.4322/acr.2024.488
Autopsy and Case Reports
Clinical Case Report and Review

A bleeding heart: case report and review of pericardial angiosarcoma

Ujjwal Madan; Himil Mahadevia; Parth Sharma; Satya Preetham Gunta; Ossama Tawfik; Karen Fritchie; Julian Magadan

Downloads: 0
Views: 230

Abstract

Abstract: Primary cardiac tumors are rare. The cardiac sarcomas are the most common malignant cardiac tumors. These tumors have a dismal prognosis with an overall median survival of 25 months. Clinical features include dyspnea, arrhythmias, pericardial effusions, heart failure, and sudden cardiac death.

The diagnosis is often challenging. Therefore, the cardiac imaging workup plays a central role in addition to a high clinical suspicion in the setting of atypical presentations that do not respond to standard therapies. The echocardiography, computed tomography, and cardiac MRI are crucial in clinching the diagnosis. Multimodal treatment with surgery, chemotherapy, and radiotherapy has been shown to improve outcomes, as opposed to using either of these modalities alone. We describe the case of a 30-year-old gentleman with COVID-19 infection who developed recurrent hemorrhagic pericardial effusions refractory to standard treatment and was eventually diagnosed as a case of pericardial angiosarcoma after his biopsy revealed the diagnosis and staging was performed using PET–CT–FDG scan. Our case re-emphasizes the importance of considering a malignant etiology early in the course of the disease presentation, especially in recurrent hemorrhagic effusions despite an inflammatory cytologic diagnosis of fluid. It also highlights the place for cardiac CT and MRI to ascertain the location and spread and to plan the further course of treatment. If diagnosed early, the estimated survival time can be prolonged by instituting a multimodal approach.

Keywords

Pericardial Effusion, Cardiac Tamponade, Sarcoma, Docetaxel, Gemcitabine

References

1 Burke AP, Cowan D, Virmani R. Primary sarcomas of the heart. Cancer. 1992;69(2):387-95. http://doi.org/10.1002/1097-0142(19920115)69:2<387::AID-CNCR2820690219>3.0.CO;2-N. PMid:1728367.

2 Look Hong NJ, Pandalai PK, Hornick JL, et al. Cardiac angiosarcoma management and outcomes: 20-year single-institution experience. Ann Surg Oncol. 2012;19(8):2707-15. http://doi.org/10.1245/s10434-012-2334-2. PMid:22476752.

3 MacGowan SW, Sidhu P, Aherne T, et al. Atrial myxoma: national incidence, diagnosis and surgical management. Ir J Med Sci. 1993;162(6):223-6. http://doi.org/10.1007/BF02945200. PMid:8407260.

4 Silverman NA. Primary cardiac tumors. Ann Surg. 1980;191(2):127-38. http://doi.org/10.1097/00000658-198002000-00001. PMid:7362282.

5 Randhawa JS, Budd GT, Randhawa M, et al. Primary cardiac sarcoma: 25-year cleveland clinic experience. Am J Clin Oncol. 2016;39(6):593-9. http://doi.org/10.1097/COC.0000000000000106. PMid:25036471.

6 Agaimy A, Rösch J, Weyand M, Strecker T. Primary and metastatic cardiac sarcomas: a 12-year experience at a German heart center. Int J Clin Exp Pathol. 2012;5(9):928-38. PMid:23119110.

7 Vander Salm TJ. Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg. 2000;12(2):89-100. http://doi.org/10.1053/ct.2000.5080. PMid:10807431.

8 Fang X, Zheng S. Primary cardiac angiosarcoma: a case report. J Int Med Res. 2021;49(8):3000605211033261. http://doi.org/10.1177/03000605211033261. PMid:34433329.

9 Blondeau P. Primary cardiac tumors: french studies of 533 cases. Thorac Cardiovasc Surg. 1990;38(Suppl 2):192-5. http://doi.org/10.1055/s-2007-1014065. PMid:2237901.

10 Senthil Kumaran S, Asif AA, Hussain H, Chatterjee T. Pericardial angiosarcoma: a diagnostic challenge. Cureus. 2021;13(5):e15350. PMid:34235027.

11 Amin A, Taheri Z, Hesami M, Alizahehasl A, Norouzi Z, Mohammadi N. Misdiagnosis of a cardiac angiosarcoma during the COVID-19 pandemic. Arq Bras Cardiol. 2023;120(7):e20220501. http://doi.org/10.36660/abc.20220501. PMid:37556653.

12 Kupsky DF, Newman DB, Kumar G, Maleszewski JJ, Edwards WD, Klarich KW. Echocardiographic Features of Cardiac Angiosarcomas: The Mayo Clinic Experience (1976-2013). Echocardiography. 2016;33(2):186-92. http://doi.org/10.1111/echo.13060. PMid:26460068.

13 Li Y, Wang B, Zhang L, et al. Rare case of pericardial angiosarcoma. Circ Heart Fail. 2018;11(10):e005342. http://doi.org/10.1161/CIRCHEARTFAILURE.118.005342. PMid:30354402.

14 Mendoza H, Nosov A, Pandit-Taskar N. Molecular imaging of sarcomas with FDG PET. Skeletal Radiol. 2023;52(3):461-75. http://doi.org/10.1007/s00256-022-04182-7. PMid:36173459.

15 Timóteo AT, Branco LM, Bravio I, et al. Primary angiosarcoma of the pericardium: case report and review of the literature. Kardiol Pol. 2010;68(7):802-5. PMid:20648441.

16 Young RJ, Natukunda A, Litière S, Woll PJ, Wardelmann E, Van Der Graaf WTA. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer. 2014;50(18):3178-86. http://doi.org/10.1016/j.ejca.2014.10.004. PMid:25459395.

17 Penel N, Blay JY, Mir O, et al. ANGIOTAX-PLUS trial: a randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS). J Clin Oncol. 2014;32(15, Suppl):10501. http://doi.org/10.1200/jco.2014.32.15_suppl.10501.

18 Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397-410. http://doi.org/10.1016/S1470-2045(17)30622-8. PMid:28882536.

19 Banavali S, Pasquier E, Andre N. Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma. Ecancermedicalscience. 2015;9:499. http://doi.org/10.3332/ecancer.2015.499. PMid:25624880.

20 Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24(1):257-63. http://doi.org/10.1093/annonc/mds237. PMid:22910841.

21 Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012;17(2):260-6. http://doi.org/10.1634/theoncologist.2011-0237. PMid:22285963.

22 Yoo C, Kim JE, Yoon SK, et al. Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib. Sarcoma. 2009;2009:360875. http://doi.org/10.1155/2009/360875. PMid:19478954.

23 Silva E, Gatalica Z, Vranic S, Basu G, Reddy SK, Voss A. Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib. Breast J. 2015;21(2):205-7. http://doi.org/10.1111/tbj.12380. PMid:25639617.

24 Kollár A, Jones RL, Stacchiotti S, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol. 2017;56(1):88-92. http://doi.org/10.1080/0284186X.2016.1234068. PMid:27838944.

25 Fields EC, Squires B, Lomas H. Treating the critically ill with radiotherapy: lessons learned from a young woman with cardiac angiosarcoma. Front Oncol. 2017;7:29. http://doi.org/10.3389/fonc.2017.00029. PMid:28303236.

26 Li X, Lan L, Hu H. Case report: primary cardiac angiosarcoma with multiple metastases. Front Cardiovasc Med. 2022;9:941967. http://doi.org/10.3389/fcvm.2022.941967. PMid:35966523.

27 Ravi V, Subramaniam A, Zheng J, et al. Clinical activity of checkpoint inhibitors in angiosarcoma: a retrospective cohort study. Cancer. 2022;128(18):3383-91. http://doi.org/10.1002/cncr.34370. PMid:35792683.
 


Submitted date:
12/22/2023

Accepted date:
04/03/2024

Publication date:
05/22/2024

664e20d3a953954bbc0e04b2 autopsy Articles
Links & Downloads

Autops Case Rep

Share this page
Page Sections